Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 1 de 1
Filtre
Ajouter des filtres








Sujet Principal
Gamme d'année
1.
Geneve; WHO; Sept. 16, 2022. 141 p. ilus, tab, graf. (WHO/2019-nCoV/therapeutics/2022.5).
non conventionnel Dans Anglais | BIGG, LILACS | ID: biblio-1393164

Résumé

The WHO Therapeutics and COVID-19: living guideline contains the Organization's most up-to-date recommendations for the use of therapeutics in the treatment of COVID-19. The latest version of this living guideline is available in pdf format (via the 'Download' button) and via an online platform, and is updated regularly as new evidence emerges. This twelfth version of the WHO living guideline now contains 19 recommendations. This latest update provides updated recommendations for remdesivir, addresses the use of combination therapy with corticosteroids, interleukin-6 (IL-6) receptor blockers and Janus kinase (JAK) inhibitors in patients with severe or critical COVID-19, and modifies previous recommendations for the neutralizing monoclonal antibodies sotrovimab and casirivimab-imdevimab in patients with non-severe COVID-19.


Sujets)
Humains , COVID-19/traitement médicamenteux , Antiviraux/usage thérapeutique , Plasma sanguin/immunologie , Ivermectine/usage thérapeutique , Colchicine/usage thérapeutique , Immunisation passive , Fluvoxamine/usage thérapeutique , Hormones corticosurrénaliennes/usage thérapeutique , Récepteurs à l'interleukine-6/usage thérapeutique , Lopinavir/usage thérapeutique , Inhibiteurs des Janus kinases/usage thérapeutique , Hydroxychloroquine/usage thérapeutique
SÉLECTION CITATIONS
Détails de la recherche